Stock Track | PTC Therapeutics Soars 6.79% After-Hours on Strong Q3 Earnings Beat

Stock Track

Nov 05, 2025

PTC Therapeutics (NASDAQ: PTCT) saw its stock price surge 6.79% in after-hours trading on Tuesday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company, focused on rare diseases, reported earnings that significantly exceeded analyst expectations.

For the quarter ended September 30, 2025, PTC Therapeutics reported total revenue of $211.0 million, a 7.23% increase from the same period last year and well above the analyst consensus estimate of $185.251 million. The company's earnings per share (EPS) of $0.20 marked a dramatic turnaround from a loss of $1.39 per share in the previous year, beating the analyst estimate of a $1.42 loss by an impressive 114.09%.

The strong performance was driven in part by the successful launch of Sephience, which generated global revenue of $19.6 million and saw 521 start forms in the US by quarter-end. Additionally, the company reported net income of $15.9 million, a significant improvement from the $106.7 million loss in the same quarter of 2024. In light of these results, PTC Therapeutics narrowed its full-year 2025 revenue guidance to $750-$800 million, signaling confidence in its continued growth trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1173936467"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173936467\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173936467?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 05:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173936467","market":"nz","top_or_hot":-1,"title":"Stock Track | PTC Therapeutics Soars 6.79% After-Hours on Strong Q3 Earnings Beat","media":"Stock Track","content":"<p>PTC Therapeutics (NASDAQ: PTCT) saw its stock price surge 6.79% in after-hours trading on Tuesday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company, focused on rare diseases, reported earnings that significantly exceeded analyst expectations.</p>\n\n<p>For the quarter ended September 30, 2025, PTC Therapeutics reported total revenue of $211.0 million, a 7.23% increase from the same period last year and well above the analyst consensus estimate of $185.251 million. The company's earnings per share (EPS) of $0.20 marked a dramatic turnaround from a loss of $1.39 per share in the previous year, beating the analyst estimate of a $1.42 loss by an impressive 114.09%.</p>\n\n<p>The strong performance was driven in part by the successful launch of Sephience, which generated global revenue of $19.6 million and saw 521 start forms in the US by quarter-end. Additionally, the company reported net income of $15.9 million, a significant improvement from the $106.7 million loss in the same quarter of 2024. In light of these results, PTC Therapeutics narrowed its full-year 2025 revenue guidance to $750-$800 million, signaling confidence in its continued growth trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | PTC Therapeutics Soars 6.79% After-Hours on Strong Q3 Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | PTC Therapeutics Soars 6.79% After-Hours on Strong Q3 Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 05:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PTC Therapeutics (NASDAQ: PTCT) saw its stock price surge 6.79% in after-hours trading on Tuesday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company, focused on rare diseases, reported earnings that significantly exceeded analyst expectations.</p>\n\n<p>For the quarter ended September 30, 2025, PTC Therapeutics reported total revenue of $211.0 million, a 7.23% increase from the same period last year and well above the analyst consensus estimate of $185.251 million. The company's earnings per share (EPS) of $0.20 marked a dramatic turnaround from a loss of $1.39 per share in the previous year, beating the analyst estimate of a $1.42 loss by an impressive 114.09%.</p>\n\n<p>The strong performance was driven in part by the successful launch of Sephience, which generated global revenue of $19.6 million and saw 521 start forms in the US by quarter-end. Additionally, the company reported net income of $15.9 million, a significant improvement from the $106.7 million loss in the same quarter of 2024. In light of these results, PTC Therapeutics narrowed its full-year 2025 revenue guidance to $750-$800 million, signaling confidence in its continued growth trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTCT","symbol_name":"PTC Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1173936467","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173936467","pubTimestamp":1762293301,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"PTC Therapeutics (NASDAQ: PTCT) saw its stock price surge 6.79% in after-hours trading on Tuesday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PTCT":"PTC Therapeutics Inc."},"translate_title":"股票追踪|PTC Therapeutics因第三季度盈利强劲而盘后飙升6.79%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTCT":1},"content_text":"PTC Therapeutics (NASDAQ: PTCT) saw its stock price surge 6.79% in after-hours trading on Tuesday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company, focused on rare diseases, reported earnings that significantly exceeded analyst expectations.\nFor the quarter ended September 30, 2025, PTC Therapeutics reported total revenue of $211.0 million, a 7.23% increase from the same period last year and well above the analyst consensus estimate of $185.251 million. The company's earnings per share (EPS) of $0.20 marked a dramatic turnaround from a loss of $1.39 per share in the previous year, beating the analyst estimate of a $1.42 loss by an impressive 114.09%.\nThe strong performance was driven in part by the successful launch of Sephience, which generated global revenue of $19.6 million and saw 521 start forms in the US by quarter-end. Additionally, the company reported net income of $15.9 million, a significant improvement from the $106.7 million loss in the same quarter of 2024. In light of these results, PTC Therapeutics narrowed its full-year 2025 revenue guidance to $750-$800 million, signaling confidence in its continued growth trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}